海外の治験の状況「前立腺癌」での検索結果
242件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A Phase I/II Open Label Study of the 17a-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
- Hormone refractory prostate cancer MedDRA version: 8.0 Classification code 10062904
- United Kingdom
- 2005-08-31
Authorised
- Protocol: HL/IDP/PTS/001 Tumour Profiling In An Open-Labelled, 2-Arm Study Investigating The Tolerability And Efficacy Of Taxotere In Patients With High Risk Prostate Cancer - GenTax
- Prostate Cancer
- United Kingdom
- 2005-07-18
Authorised
- "PHASE III RANDOMISED AND MULTICENTRE TRIAL OF ADJUVANT ANDROGEN DEPRIVATION COMBINED WITH HIGH-DOSE THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY IN INTERMEDIATE-OR HIGH-RISK LOCALIZED PROSTATE CANCER" “Ensayo fase III aleatorizado y multicéntrico de deprivación androgénica adyuvante en combinación con radioterapia conformacional tridimensional altas dosis en cáncer de próstata localizado riesgo intermedio-alto”
- Cáncer de Próstata localizado
- Spain
- 2006-05-09
Authorised
- A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer
- Chemo-naive hormone refractory prostate cancer
- United Kingdom
- 2006-01-20
Authorised
- An open randomized phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2 - AdPro
- Men, 18-70 years old, who have had radical prostatectomy due to prostate cancer and with a high grade pT3 or margin positive pT2 tumour may be candidates for the study.
- Denmark, Finland, Iceland, Sweden
- 2005-06-30
Authorised
- An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-003
- Hormone refractory prostate cancer MedDRA version: 14.1 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- United Kingdom
- 2008-06-27
Authorised
- ANDROGEN DEPRIVATION THERAPY WITHDRAWAL VERSUS MAINTENANCE AND INTERMITTENT DOCETAXEL THERAPY VERSUS CONTINUOUS ADMINISTRATION IN PATIENTS WITH PROSTATE CANCER RESISTANT TO CHEMICAL CASTRATION - PON-PC-02
- PROSTATIC ADENOCARCINOMA CHEMICAL CASTRATION RESISTANT MedDRA version: 9.1 Level: HLT Classification code 10018187
- Italy
- 2010-05-18
Authorised
- Multicenter clinical trial, randomized phase II "window of opportunity" which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prostate cancer at high risk. (multicenter study).
- PROSTATE CANCER PATIENTS WITH HIGH RISK;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2013-05-17
Authorised
- Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy
- high-risk prostata cancer patients;Therapeutic area: Diseases [C] - Cancer [C04];high-risk prostata cancer patients;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2013-04-19
Authorised
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Metastatic castration-resistant prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Japan, Korea, Republic of, Netherlands, Norway, Spain, Sweden, Taiwan, United Kingdom, United States
- 2017-01-03